Page 35 - 2020_07-Haematologica-web

Personalized management of MDS
2019;133(25):2724-2728.
74. Sebert M, Passet M, Raimbault A, et al.
Germline DDX41 mutations define a signif- icant entity within adult MDS/AML patients. Blood. 2019;134(17):1441-1444.
75. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
76. Germing U, Hildebrandt B, Pfeilstöcker M, et al. Refinement of the international prog- nostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia. 2005;19(12):2223-2231.
77. Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood. 2008; 112(11):640.
78. Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754-762.
79. Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011;29(16):2240-2246.
80. Stauder R, Nösslinger T, Pfeilstöcker M, et al. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Cancer Netw. 2008;6(9):927-934.
81. Schanz J, Tüchler H, Solé F, et al. New com- prehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8): 820-829.
center study. Leuk Res. 2014;38(1):57-64. 89. Bejar R, Papaemmanuil E, Haferlach T, et al. Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analy- sis of combined datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood.
2015;126(23):907.
90. Nazha A, Al-Issa K, Hamilton B, et al.
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. Leukemia. 2017;31(12):2848-2850.
91. Tefferi A, Gangat N, Mudireddy M, et al. Mayo alliance prognostic model for myelodysplastic syndromes: integration of genetic and clinical information. Mayo Clin Proc. 2018;93(10):1363-1374.
92. Bernard E, Nannya Y, Yoshizato T, et al. TP53 state dictates genome stability, clinical presentation and outcomes in myelodys- plastic syndromes. Blood. 2019;134 (Suppl_1):675.
93. Duetz C, Bachas C, Westers TM, et al. Computational analysis of flow cytometry data in hematological malignancies: future clinical practice? Curr Opin Oncol. 2020;32(2):162-169.
94. Hansen JW, Pedersen DA, Larsen LA, et al. Clonal hematopoiesis in elderly twins: con- cordance, discordance, and mortality. Blood. 2020;135(4):261-268.
95. Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129(25):3371-3378.
96. Luis TC, Wilkinson AC, Beerman I, et al. Biological implications of clonal hematopoiesis. Exp Hematol. 2019;77:1-5.
97. Breccia M, Federico V, Latagliata R, et al. Evaluation of comorbidities at diagnosis pre- dicts outcome in myelodysplastic syndrome patients. Leuk Res. 2011;35(2):159-162.
98. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodys- plasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007; 25(27):4246-4254.
99. de Swart L, Crouch S, Hoeks M, et al. Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients. Haematologica. 2020;105(3):632- 639.
100. Nilsson-Ehle H, Birgegard G, Samuelsson J, et al. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of >/=120 g/L with darbepoetin alfa +/- filgrastim or ery- throcyte transfusions. Eur J Haematol. 2011;87(3):244-252.
101. Stanworth SJ, Killick S, McQuilten ZK, et al. Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. Br J Haematol. 2020;189(2):279-290.
102. Mittelman M, Platzbecker U, Afanasyev B, et al. Eltrombopag for advanced myelodys- plastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018; 5(1):e34-e43.
103.Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018;132(25):2629-2638.
104.Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847-2852.
105.Malcovati L, Porta MGD, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clini- cal decision making. J Clin Oncol. 2005;23(30):7594-7603.
106.Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfu- sional iron overload in adults. N Engl J Med. 1981;304(6):319-324.
107. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998;850:191-201.
108. Cabantchik ZI, Breuer W, Zanninelli G, et al. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18(2):277- 287.
109. Cortelezzi A, Cattaneo C, Cristiani S, et al. Non-transferrin-bound iron in myelodys- plastic syndromes: a marker of ineffective erythropoiesis? Hematol J. 2000;1(3):153- 158.
110. Greenberg PL, Rigsby CK, Stone RM, et al. NCCN Task Force: transfusion and iron overload in patients with myelodysplastic syndromes. J Natl Compr Cancer Netw. 2009;7(Suppl_9):S-1-S-16.
111.De Swart L, Smith A, Fenaux P, et al. Transfusion-dependency is the most impor- tant prognostic factor for survival in 1000 newly diagnosed MDS patients with low- and intermediate-1 risk MDS in the European LeukemiaNet MDS registry. Blood. 2011;118(21):2775.
112. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the out- come of patients with myelodysplastic syn- drome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96 (10):1433-1440.
113. Lyons RM, Marek BJ, Paley C, et al. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes:registry analysis at 5 years. Leuk Res. 2017;56:88-95.
114.Leitch HA, Parmar A, Wells RA, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: an MDS‐CAN analysis. Br J Haematol. 2017;179(1):83-97.
115. Mainous AG 3rd, Tanner RJ, Hulihan MM, et al. The impact of chelation therapy on survival in transfusional iron overload: a meta‐analysis of myelodysplastic syn- drome. Br J Haematol. 2014;167(5):720- 723.
116. Zeidan AM, Giri S, DeVeaux M, et al. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes. Ann Hematol. 2019;98(2):339-350.
117. Hoeks M, Yu G, Langemeijer S, et al. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica. 2020;105 (3):640-651.
118.Angelucci E, Li J, Greenberg P, et al. Iron chelation in transfusion-dependent low/intermediate-1-risk myelodysplastic syndromes patients: a randomized trial. Ann Intern Med. 2020;172(8):513-522.
82. Della Porta M, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and compari- son with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015;29(7):1502-1513.
83. https://mds-europe.eu/management.
84. Mishra A, Corrales‐Yepez M, Ali NA, et al. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
Am J Hematol. 2013;88(7):566-570.
85. Lamarque M, Raynaud S, Itzykson R, et al. The revised IPSS is a powerful tool to evalu- ate the outcome of MDS patients treated with azacitidine: the GFM experience.
Blood. 2012;120(25):5084-5085.
86. Pfeilstöcker M, Tüchler H, Schönmetzler A,
et al. Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for myelodysplastic syndromes. Leuk Res. 2012;36(2):132-139.
87. Voso MT, Fenu S, Latagliata R, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolu- tion of myelodysplastic syndromes signifi- cantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol. 2013;31(21):2671- 2677.
88. Neukirchen J, Lauseker M, Blum S, et al. Validation of the revised international prog- nostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multi-
haematologica | 2020; 105(7)
1777